Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Bone Metastases|HER2-positive Breast Cancer|Liver Metastases|Lung Metastases|Recurrent Breast Cancer|Soft Tissue Metastases|Stage IV Breast Cancer
Interventions: RADIATION: fludeoxyglucose F 18|PROCEDURE: positron emission tomography|PROCEDURE: computed tomography|BIOLOGICAL: trastuzumab|RADIATION: copper Cu 64-DOTA-trastuzumab|PROCEDURE: positron emission tomography|BIOLOGICAL: ado-trastuzumab emtansine|OTHER: laboratory biomarker analysis
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)